Targeting thyroid diseases with TSH receptor analogs

Endocrinologia y Nutricion

Volumn 60, Issue 10, 2013, Pages 590-598

  Galofré, Juan C ^a   Chacón, Ana M ^a   Latif, Rauf ^b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Graves' disease; Small molecules; Thyroid; Thyroid cancer; Thyrotropin (TSH); TSH receptor

Indexed keywords

FOLLITROPIN RECEPTOR; LEVOTHYROXINE; LIOTHYRONINE; RADIOACTIVE IODINE; THYROTROPIN; THYROTROPIN RECEPTOR;

ENDOCRINE OPHTHALMOPATHY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; OSSIFICATION; OSTEOPOROSIS; PROTEIN STRUCTURE; SHORT SURVEY; THYROID CANCER; THYROID DISEASE; THYROIDECTOMY; THYROID DISEASES; THYROID NEOPLASMS;

GRAVES DISEASE; HUMANS; RECEPTORS, THYROTROPIN; THYROID DISEASES; THYROID NEOPLASMS;

EID: 84889094680     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.12.008     Document Type: Short Survey

References (47)

1. Graves P.N., Davies T.F. New insights into the thyroid-stimulating hormone receptor. The major antigen of Graves' disease. Endocrinol Metab Clin North Am 2000, 29:267-286.
2. Rapoport B., Chazenbalk G.D., Jaume J.C., McLachlan S.M. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev 1998, 19:673-716.
3. Sanders J., Oda Y., Roberts S.A., Maruyama M., Furmaniak J., Smith B.R. Understanding the thyrotropin receptor function-structure relationship. Baillieres Clin Endocrinol Metab 1997, 11:451-479.
4. Davies T., Marians R., Latif R. The TSH receptor reveals itself. J Clin Invest 2002, 110:161-164.
5. Latif R., Morshed S.A., Zaidi M., Davies T.F. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization cleavage and signaling. Endocrinol Metab Clin North Am 2009, 38:319-341.
6. Chazenbalk G.D., Tanaka K., McLachlan S.M., Rapoport B. On the functional importance of thyrotropin receptor intramolecular cleavage. Endocrinology 1999, 140:4516-4520.
7. Ladenson P.W., Kristensen J.D., Ridgway E.C., Olsson A.G., Carlsson B., Klein I., et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010, 362:906-916.
8. Goldman S., McCarren M., Morkin E., Ladenson P.W., Edson R., Warren S., et al. DITPA (35-diiodothyropropionic acid) a thyroid hormone analog to treat heart failure: phase II trial veterans affairs cooperative study. Circulation 2009, 119:3093-3100.
9. Davies T.F., Ando T., Lin R.Y., Tomer Y., Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J Clin Invest 2005, 115:1972-1983.
10. Mizutori Y., Chen C.R., McLachlan S.M., Rapoport B. The thyrotropin receptor hinge region is not simply a scaffold for the leucine-rich domain but contributes to ligand binding and signal transduction. Mol Endocrinol 2008, 22:1171-1182.
11. Sanders J., Chirgadze D.Y., Sanders P., Baker S., Sullivan A., Bhardwaja A., et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid 2007, 17:395-410.
12. Sanders P., Young S., Sanders J., Kabelis K., Baker S., Sullivan A., et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol 2011, 46:81-99.
13. Allgeier A., Offermanns S., Van Sande J., Spicher K., Schultz G., Dumont J.E. The human thyrotropin receptor activates G-proteins Gs and Gq/11. J Biol Chem 1994, 269:13733-13735.
14. Kimura T., Van Keymeulen A., Golstein J., Fusco A., Dumont J.E., Roger P.P. Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 2001, 22:631-656.
15. Marshall C.J. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 1994, 4:82-89.
16. Stoyanov B., Volinia S., Hanck T., Rubio I., Loubtchenkov M., Malek D., et al. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. Science 1995, 269:690-693.
17. 2+-binding proteins. EMBO J 2004, 23:312-321.
18. Brewer C., Yeager N., Di Cristofano A. Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT. Cancer Res 2007, 67:8002-8006.
19. Galofré J.C., Duntas L.H., Premawardhana L.D., Davies T.F. Advances in Graves' disease. J Thyroid Res 2012, 2012:809231.
20. Bahn R.S., Burch H.B., Cooper D.S., Garber J.R., Greenlee M.C., Klein I., et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011, 21:593-646.
21. Cooper D.S. Antithyroid drugs. N Engl J Med 2005, 352:905-917.
22. Klein I., Becker D.V., Levey G.S. Treatment of hyperthyroid disease. Ann Intern Med 1994, 121:281-288.
23. Guo T. Small melecule agonists and antagonists for the LH and FSH receptors. Expert Opinion 2005, 15:1555.
24. Jäschke H., Neumann S., Moore S., Thomas C.J., Colson A.O., Costanzi S., et al. A low molecular weight agonist signals by binding to the transmembrane domain of thyroid-stimulating hormone receptor (TSHR) and luteinizing hormone/chorionic gonadotropin receptor (LHCGR). J Biol Chem 2006, 281:9841-9844.
25. Neumann S., Huang W., Titus S., Krause G., Kleinau G., Alberobello A.T., et al. Small-molecule agonists for the thyrotropin receptor stimulate thyroid function in human thyrocytes and mice. Proc Natl Acad Sci USA 2009, 106:12471-12476.
26. Neumann S., Kleinau G., Costanzi S., Moore S., Jiang J.K., Raaka B.M., et al. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology 2008, 149:5945-5950.
27. Neumann S., Eliseeva E., McCoy J.G., Napolitano G., Giuliani C., Monaco F., et al. A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor. J Clin Endocrinol Metab 2011, 96:548-554.
28. van Koppen C.J., de Gooyer M.E., Karstens W.J., Plate R., Conti P.G., van Achterberg T.A., et al. Mechanism of action of a nanomolar potent allosteric antagonist of the thyroid-stimulating hormone receptor. Br J Pharmacol 2012, 165:2314-2324.
29. Valyasevi R.W., Harteneck D.A., Dutton C.M., Bahn R.S. Stimulation of adipogenesis peroxisome proliferator-activated receptor-gamma (PPARgamma) and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J Clin Endocrinol Metab 2002, 87:2352-2358.
30. Kumar S., Nadeem S., Stan M.N., Coenen M., Bahn R.S. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol 2011, 46:155-163.
31. Bahn R.S., Dutton C.M., Natt N., Joba W., Spitzweg C., Heufelder A.E. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998, 83:998-1002.
32. Neumann S., Pope A., Geras-Raaka E., Raaka B.M., Bahn R.S., Gershengorn M.C. A drug-like antagonist inhibits thyrotropin receptor-mediated stimulation of cAMP production in Graves' orbital fibroblasts. Thyroid 2012, 22:839-843.
33. Santos Palacios S., Pascual Corrales E., Galofré J.C. Management of subclinical hyperthyroidism. Int J Endocrinol Metab 2012, 10:490-496.
34. Gómez Sáez J.M. Is our approach to thyroid nodules and differentiated thyroid carcinoma in agreement with the American guideline and European consensus. Endocrinol Nutr 2010, 57:357-363.
35. Neumann S., Huang W., Eliseeva E., Titus S., Thomas C.J., Gershengorn M.C. A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology 2010, 151:3454-3459.
36. Titus S., Neumann S., Zheng W., Southall N., Michael S., Klumpp C., et al. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. J Biomol Screen 2008, 13:120-127.
37. Gozu H.I., Lublinghoff J., Bircan R., Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol 2010, 322:125-134.
38. Alberti L., Proverbio M.C., Costagliola S., Romoli R., Boldrighini B., Vigone M.C., et al. Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 2002, 87:2549-2555.
39. Allen M.D., Neumann S., Gershengorn M.C. Small-molecule thyrotropin receptor agonist activates naturally occurring thyrotropin-insensitive mutants and reveals their distinct cyclic adenosine monophosphate signal persistence. Thyroid 2011, 21:907-912.
40. Wiersinga W.M. Do we need still more trials on T4 and T3 combination therapy in hypothyroidism. Eur J Endocrinol 2009, 161:955-959.
41. Abe E., Marians R.C., Yu W., Wu X.B., Ando T., Li Y., et al. TSH is a negative regulator of skeletal remodeling. Cell 2003, 115:151-162.
42. Zaidi M., Davies T.F., Zallone A., Blair H.C., Iqbal J., Moonga S.S., et al. Thyroid-stimulating hormone thyroid hormones and bone loss. Curr Osteoporos Rep 2009, 7:47-52.
43. Sun L., Vukicevic S., Baliram R., Yang G., Sendak R., McPherson J., et al. Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss. Proc Natl Acad Sci USA 2008, 105:4289-4294.
44. Sun L., Davies T.F., Blair H.C., Abe E., Zaidi M. TSH and bone loss. Ann N Y Acad Sci 2006, 1068:309-318.
45. Agrawal M., Zhu G., Sun L., Zaidi M., Iqbal J. The role of FSH and TSH in bone loss and its clinical relevance. Curr Osteoporos Rep 2010, 8:205-211.
46. Baliram R., Sun L., Cao J., Li J., Latif R., Huber A.K., et al. Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling. J Clin Invest 2012, 122:3737-3741.
47. Gershengorn M.C., Neumann S. Update in TSH Receptor Agonists and Antagonists. J Clin Endocrinol Metab 2012, 97:4287-4292.